Discussion
An analysis of published studies found lower one-year death rates with rituximab than with cyclophosphamide among people with ANCA-associated vasculitis (AAV). The findings suggest a possible survival advantage with rituximab. This pattern was particularly evident in studies involving patients with lower disease activity at diagnosis or in which most…